- Home
- EDSA vs LAES Comparison
EDSA vs LAES Comparison
Compare EDSA & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- LAES
- Stock Information
- Founded
- EDSA 2015
- LAES 2022
- Country
- EDSA Canada
- LAES Switzerland
- Employees
- EDSA N/A
- LAES N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- LAES Semiconductors
- Sector
- EDSA Health Care
- LAES Technology
- Exchange
- EDSA Nasdaq
- LAES Nasdaq
- Market Cap
- EDSA 6.1M
- LAES 10.7M
- IPO Year
- EDSA N/A
- LAES N/A
- Fundamental
- Price
- EDSA $1.73
- LAES $2.75
- Analyst Decision
- EDSA Strong Buy
- LAES Strong Buy
- Analyst Count
- EDSA 1
- LAES 1
- Target Price
- EDSA $21.00
- LAES $1.75
- AVG Volume (30 Days)
- EDSA 30.6K
- LAES 55.3M
- Earning Date
- EDSA 02-07-2025
- LAES 09-25-2024
- Dividend Yield
- EDSA N/A
- LAES N/A
- EPS Growth
- EDSA N/A
- LAES N/A
- EPS
- EDSA N/A
- LAES N/A
- Revenue
- EDSA N/A
- LAES $20,135,000.00
- Revenue This Year
- EDSA N/A
- LAES N/A
- Revenue Next Year
- EDSA N/A
- LAES N/A
- P/E Ratio
- EDSA N/A
- LAES N/A
- Revenue Growth
- EDSA N/A
- LAES N/A
- 52 Week Low
- EDSA $1.55
- LAES $0.29
- 52 Week High
- EDSA $5.99
- LAES $3.95
- Technical
- Relative Strength Index (RSI)
- EDSA 31.51
- LAES 72.15
- Support Level
- EDSA $1.73
- LAES $1.98
- Resistance Level
- EDSA $1.99
- LAES $3.46
- Average True Range (ATR)
- EDSA 0.19
- LAES 0.43
- MACD
- EDSA 0.02
- LAES 0.19
- Stochastic Oscillator
- EDSA 18.00
- LAES 77.17
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. Its vaultIC range offers a complete set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.